Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

According to Dr Raja, a "sweet, fruity odour" might be a sign of diabetes. The sweet scent can indicate high levels of ...

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

Hyperglycemia, including diabetic ketoacidosis, has been reported ... hyperglycemia, and rash. Please see the full Prescribing Information, including Medication Guide. About Soleno Therapeutics ...

Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis UNLOXCYT can cause ... UNLOXCYT can cause immune-mediated rash or dermatitis. Bullous and exfoliative dermatitis, including ...

Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and ...

Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and ... colitis, and diabetic ketoacidosis (1% each). Fatal adverse reactions occurred in 0.2% including ...